SCYNEXIS

SCYX68

Penny Stock

$1.20arrow_drop_up2.94%$0.03

Penny Stock

SCYX68

$1.20

arrow_drop_up2.94%$0.03

Penny Stock

Performance History

Key Stats
Open	$1.18
Prev. Close	$1.19
EPS	-0.76
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$45.53M
PE Ratio	-

	LOW	HIGH
Day Range	1.17	1.22
52 Week Range	1.14	3.07

Ratios

Revenue	-





EPS	-0.76

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About SCYNEXIS (SCYX)

SCYNEXIS Inc (SCYX) is a biotechnology company that focuses on the discovery, development, and commercialization of novel anti-infectives to address unmet needs in the treatment of infectious diseases. The company's lead product candidate is ibrexafungerp (formerly known as SCY-078), a novel oral and intravenous (IV) antifungal agent that is being developed for the treatment of fungal infections, including vulvovaginal candidiasis (VVC) and invasive candidiasis. This innovative drug has the potential to become a first-line treatment option for patients suffering from these debilitating infections. With its broad-spectrum antifungal activity and favorable safety profile, ibrexafungerp has generated significant interest within the medical community and pharmaceutical industry.

The historical stock price of SCYNEXIS Inc (SCYX) has shown some volatility, but overall, the company has demonstrated steady growth. Over the past five years, the stock price has experienced fluctuations, reaching a high of $18.54 per share in March 2018 and a low of $2.36 per share in February 2021. Despite these fluctuations, SCYNEXIS has managed to maintain a strong market position and attract investor interest. The company's market capitalization currently stands at around $300 million, reflecting the market's confidence in SCYNEXIS's potential for growth and success in the biopharmaceutical industry.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO: Mr. David Gonzalez Angulo M.D.
Headquarters: Jersey City
Employees: 36
Exchange: NASDAQ

Keep an eye on SCYNEXIS

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is SCYNEXIS 's (SCYX) price per share?

The current price per share for SCYNEXIS (SCYX) is $1.2. The stock has seen a price change of $0.04 recently, indicating a 2.94% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for SCYNEXIS (SCYX)?

For SCYNEXIS (SCYX), the 52-week high is $3.07, which is 155.83% from the current price. The 52-week low is $1.14, the current price is 5.17% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is SCYNEXIS (SCYX) a growth stock?

SCYNEXIS (SCYX) has shown an average price growth of -4.13% over the past three years. It has received a score of 7 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying SCYNEXIS as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is SCYNEXIS (SCYX) stock price performance year to date (YTD)?

As of the latest data, SCYNEXIS (SCYX) has a year-to-date price change of -45.7%. Over the past month, the stock has experienced a price change of -18.37%. Over the last three months, the change has been -28.57%. Over the past six months, the figure is -52.57%. Looking at a longer horizon, the five-year price change stands at -89.09%.

help

Is SCYNEXIS (SCYX) a profitable company?

SCYNEXIS (SCYX) has a net income of $67.04M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 88.85% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.56K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $124.52M. Operating income is noted at $72.67M. Furthermore, the EBITDA is $74.21M.

help

What is the market capitalization of SCYNEXIS (SCYX)?

SCYNEXIS (SCYX) has a market capitalization of $45.53M. The average daily trading volume is 1.2, indicating the stock's liquidity and investor engagement.

News

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

EARNINGS RELEASES AND OPERATING RESULTS

May 8, 2024

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

PRODUCT / SERVICES ANNOUNCEMENT

CALENDAR OF EVENTS

Apr 30, 2024

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

CALENDAR OF EVENTS

Apr 9, 2024

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

EARNINGS RELEASES AND OPERATING RESULTS

Mar 28, 2024

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

CALENDAR OF EVENTS

Jan 30, 2024

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference